Ocean Biomedical, Inc. announced that Scientific Co-founder Dr. Jack A. Elias, MD received notice from the European Patent Office of its intention to grant European patent rights for Methods and Compositions relating to the treatment of fibrosis using Ocean's anti-Chitinase 1 small molecule candidate ("Small Molecule X"), a new target discovered by Dr. Elias that appears to be a major factor in controlling--and inhibiting--fibrosis progression. Ocean's approach has shown an 85%--90% reduction in collagen accumulation in four "gold standard" IPF and HPS pulmonary fibrosis animal models. This treatment approach is anticipated to be well-tolerated based on data from original (non-Ocean) clinical studies and recent EPA data.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | +2.80% | -.--% | +122.73% |
30/05 | Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down | MT |
15/04 | Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+122.73% | 4.95Cr | |
+11.91% | 12TCr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr |
- Stock Market
- Equities
- OCEA Stock
- News Ocean Biomedical, Inc.
- Ocean Biomedical Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery to Europe